RUO

Peptisynlab · Research Compound

Tesamorelin 5mg

A 44-amino-acid synthetic analog of human growth-hormone-releasing hormone (GHRH), stabilized with an N-terminal trans-3-hexenoyl moiety. The reference GHRH-analog peptide for visceral-adiposity research.

GHRH Analog Pituitary GH Axis Visceral Lipolysis RUO

CAS Number: 261376-48-5
Molecular Formula: C330H439N83O99S
Molecular Weight: 7197.9 g/mol
Purity: ≥ 99% HPLC
Vial Content: 5 mg lyophilized
Length: 44 residues

Half-life ~26 min Short systemic half-life · daily dosing in research

Reconstitution 2 mL bac water Yields 2.5 mg/mL working concentration

Storage −20 °C / 2–8 °C Lyophilized: −20 °C · Reconstituted: 2–8 °C

Route (Research) Subcutaneous Standard route in published literature

Overview

Tesamorelin is a stabilized synthetic analog of endogenous human GHRH (44-residue form), modified with an N-terminal trans-3-hexenoic-acid attachment that resists proteolytic degradation. The result is a peptide that retains full GHRH-receptor agonist activity but with sufficient stability for reproducible research dosing.

By stimulating endogenous, pulsatile growth-hormone secretion from the anterior pituitary, tesamorelin produces a more physiological GH profile than direct exogenous GH administration. This makes it the most cited research peptide for studying visceral fat reduction, IGF-1 axis modulation and metabolic phenotype.

Mechanism of Action — How It Works

Tesamorelin acts at the GHRH receptor on pituitary somatotrophs, restoring or amplifying physiological GH pulsatility.

GHRH Receptor Activation

Binds the pituitary GHRH receptor, triggering cAMP-dependent release of growth hormone in pulsatile fashion.

IGF-1 Elevation

Hepatic GH signaling increases circulating IGF-1, the principal mediator of GH downstream effects on tissues.

Visceral Lipolysis

GH preferentially mobilizes lipid from visceral adipose tissue via hormone-sensitive lipase, producing the characteristic VAT-reduction profile.

Stabilized Backbone

The N-terminal trans-3-hexenoic group resists DPP-IV cleavage, extending peptide stability without disrupting receptor binding.

Research Effects on the Body

Endpoints reported in metabolic-research literature.

Visceral fat reduction: consistent, dose-dependent reductions in VAT in HIV-associated lipodystrophy research and adjacent metabolic models.
Trunk-fat decrease: measurable reduction in central adiposity by imaging endpoints.
IGF-1 elevation: rises into the upper physiological range under typical research dosing.
Peptisynlab profile: reductions in triglycerides and apolipoprotein-B in research cohorts.
Lean-mass preservation: typically preserved or slightly increased relative to baseline.
Cognitive endpoints: investigated in research on age-related cognitive function.

Reconstitution — Dilution Math

Tesamorelin is supplied lyophilized. Reconstitute with bacteriostatic water. Volumes shown for the 5 mg vial — units refer to insulin syringe (1 mL = 100 IU).

Bac Water	Concentration	500 mcg dose	1 mg dose	2 mg dose
1 mL	5 mg/mL	0.10 mL · 10 IU	0.20 mL · 20 IU	0.40 mL · 40 IU
2 mL	2.5 mg/mL	0.20 mL · 20 IU	0.40 mL · 40 IU	0.80 mL · 80 IU
0.25 mL	20 mg/mL	0.025 mL · 2.5 IU	0.05 mL · 5 IU	0.10 mL · 10 IU

Standardized 20 mg/mL working reference: 0.25 mL bac water with this 5 mg vial reaches the same 20 mg/mL baseline used across the catalog.

Dosing Reference (Research Context)

Ranges below are from published clinical-research literature, listed for laboratory reference only.

Phase	Reported Range	Typical Frequency	Vial Duration (5 mg)
Standard research	1 mg	Once daily (evening)	~5 days
Approved-use research	2 mg	Once daily	2.5 days
Course duration	—	Typically 12 – 26 weeks	Multiple vials per course

Half-Life, Onset and Duration

Half-life: approximately 26 minutes (short, like endogenous GHRH).

Onset: a GH pulse appears within 15 – 30 minutes of administration; IGF-1 elevation observable within days.

Duration of effect: each dose produces one pulsatile GH burst. Daily dosing is required to sustain the IGF-1 elevation. Body-composition effects accumulate over 12 – 26 weeks of consistent research dosing.

Wash-out: IGF-1 returns toward baseline over 2 – 4 weeks of discontinuation.

Storage & Stability

Lyophilized vial: store at −20 °C for long-term stability.
Reconstituted solution: use immediately or within 24 – 48 hours when stored at 2–8 °C; tesamorelin is more sensitive in solution than other GHRH analogs.
Light: protect from direct light.
Handling: gentle swirl only; do not shake.

Important Considerations

Research Use Only. Information presented is for in-vitro and laboratory-research contexts. Tesamorelin on this site is not a finished pharmaceutical product, is not intended for diagnosis, treatment or prevention of disease, and is not for human or veterinary use.